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Abstract
Ultraviolet A1 (UVA1) phototherapy (spectral range 340-400 nm) is a well-established 
treatment option for various skin diseases such as localized scleroderma. Recent im-
provements of conventional UVA1 light sources (metal-halide or fluorescent lamps) 
have brought attention to a new light-emitting diode (LED) technology with remark-
able advantages in handling and clinical routine. This study provides a preclinical his-
tological and molecular evaluation of an LED-based UVA1 prototype with a narrower 
spectral range (360-400 nm) for treating localized scleroderma. Scleroderma mouse 
models and fibroblasts in vitro were exposed to LED-based UVA1 phototherapy or 
to irradiation with a commercially available metal-halide lamp emitting low-dose 
(20, 40 J/cm2), medium-dose (60 J/cm2) and high-dose (80, 100 J/cm2) UVA1 light. 
Both UVA1 light sources affected inflammatory genes (IL-1α and IL-6) and growth 
factors (TGFß-1 and TGFß-2). Increased collagen type 1 was reduced after UVA1 pho-
totherapy. Matrix metalloproteinase-1 was more enhanced after a medium dose of 
LED-based UVA1 phototherapy than after conventional treatment. In vivo, dermal 
thickness and the amount of collagen were reduced after both treatment methods. 
Remarkably, myofibroblasts were more effectively reduced by a medium dose of 
LED-based UVA1 phototherapy. The study indicates that LED-based UVA1 photo-
therapy yields similar or even better results than conventional treatment. In terms 
of biosafety and patient comfort, LED-based UVA1 phototherapy offers clear advan-
tages over conventional treatment because of the use of a narrower and less harm-
ful UVA1 spectrum, less heat generation and shorter treatment times at the same 
irradiation intensity. Clinical studies are required to confirm these results in patients 
with localized scleroderma.
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1  | INTRODUC TION
Localized scleroderma (LS) is a distinctive inflammatory disease 
that leads to sclerosis of the skin and subcutaneous tissues.[1-4] 
Management of LS is difficult, and no causal therapy is available so 
far. Topical and systemic immunosuppressants such as corticoste-
roids are commonly used as anti-fibrotic agents but with consider-
able side effects and limited efficacy.[5,6] The beneficial effects of 
different forms of phototherapy in the treatment of LS have been 
described in many studies.[7-13] The development of UVA1 photo-
therapy (340-400 nm) has highly improved treatment of LS.[14,15] 
Because UVA1 light is less erythematogenic than broadband UVA, 
it is possible to apply much higher doses of UVA1 without the risk of 
sunburn.UVA1 light penetrates deeper into the skin than UVB and 
UVA2.
[16] In the first prospective study on LS, high-dose UVA1 light 
(130 J/cm2) was highly effective in reducing skin sclerosis, and some 
patients even showed complete clearance.[11] Lower UVA1 doses 
(30 J/cm2) were also highly effective and well-tolerated by patients 
with LS who showed a significant reduction in skin thickness.[17]
Commercially available UVA1 light sources for therapeutic use are 
fluorescent lamps (ie TL10R 100W, Philips) or high-output metal-halide 
lamps (ie Sellamed 4000W, Sellas Medizinische Geräte GmbH). Low-
dose to medium-dose UVA1 phototherapy is usually conducted by 
means of fluorescent lamp cubicles, that is full-body UV cabins, allow-
ing the irradiation of large body areas; in contrast, metal-halide lamps 
are more often used for high-dose UVA1 treatments.
[14,18,19] Despite 
the therapeutic success of conventional lamps in the treatment of LS, 
these light sources should be further developed in terms of biosafety 
and patient comfort. For patients, conventional therapy involves long 
irradiation times per therapy session (up to 60 minutes) and treatment 
durations (up to 40 sessions) as well as possible discomfort due to se-
vere heat from the light sources (up to 40°C). The new light-emitting 
diode (LED) technology provides remarkable advantages over conven-
tional treatment. The higher power of the LEDs significantly reduces 
the treatment time per session. Furthermore, LEDs only develop 
very low waste heat. LED technology also allows the manufacturing 
of small hand-operated UVA1 devices that require less space. In this 
way, only skin areas requiring treatment may be targeted. Irradiation 
of healthy tissue can be avoided when only circumscribed areas need 
to be treated. The narrower UVA1 spectrum due to the mixture of dif-
ferent LEDs is also of importance. Patient safety could be improved 
by eliminating potentially more damaging short-wave UVA1 radiation 
(340-360 nm). This study investigated the—so far—unresolved ques-




The in vitro study included human dermal fibroblasts from n = 6 dif-
ferent donors (#231340, #7F3943, #7F3950, #2F0621, #9F0438 
and #9F0889) purchased from CellSystems® (Biotechnologie 
Vertrieb GmbH). Fibroblasts were maintained in Dulbecco's modi-
fied Eagle's medium (DMEM) (Thermo Fisher Scientific) and sup-
plemented with 10% fetal bovine serum (both from PAN Biotech) 
and 1% penicillin-streptomycin, as well as 1% L-glutamine (both from 
Sigma-Aldrich). All cells were cultured in 75 cm2 FalconTM Flasks 
(Corning Inc), incubated under humid conditions in a 5% CO2 incuba-
tor at 37°C and split 1:3 every 3 days.
2.2 | Animals and treatment groups
The mouse experiments were conducted with129Sv/Ev male mice 
(original strain from Robertson Lab of Dunn School Pathology of 
the University of Oxford, UK). All animals (n = 6 animals per group) 
were between 6 and 8 weeks old at the start of the study and 
were divided into experimental groups according to their cage oc-
cupation. Mice were maintained under specific pathogen-free and 
controlled conditions (22°C, 55% humidity and 12 hours day/night 
rhythm) and had free access to water and chow. They received 
human care in compliance with the guidelines outlined in the Guide 
for the Care and Use of Laboratory Animals. The backs of the mice 
were shaved (2 × 2 cm2). The animals were subjected to a well-
established bleomycin-induced scleroderma model[20-23] based on 
the study by Yamamoto et al on BALB/C mice[23] with small modifi-
cations adapted for the 129Sv/Ev mouse strain. Mice in the experi-
mental groups (group 2-6) received local subcutaneous injections 
of 100 µL bleomycin (500 µg/mL; Hexal AG Holzkirchen) five times 
a week within 6 weeks as well as further injections 1-2 times per 
week (over the 6 weeks of phototherapy) to maintain the local scle-
rosis status. Control group 1 received subcutaneous injections of 
100 µl of phosphate-buffered saline (PBS) (Sigma-Aldrich) instead 
of bleomycin (Table S1). To induce a comparable level of local fi-
brosis that was as homogeneous as possible, the injections were 
always given by the same person. Groups 3-6 received photothera-
peutic treatment for 30 days (5 times per week). The high-dose 
UVA1 groups (groups 3 and 4) were treated for 3330 minutes (= 
100 J/cm2) per session and the medium-dose UVA1 groups (groups 
5 and 6) for 2000 minutes (= 60 J/cm2). Groups 3 and 5 were ex-
posed to irradiation with the metal-halide lamp and groups 4 and 
6 to irradiation with the LED prototype (Table S1). The mice were 
treated in their usual cages to avoid any additional stress. After 
UVA1 therapy, all animals were killed by cervical dislocation, and 
the bleomycin-treated or PBS-treated skin area was removed and 
subdivided for histological preparation or molecular biological 
examination.
2.3 | UVA1 devices, illumination set-up, and 
treatment of cells and mice
This UVA1 phototherapy study included two UVA1 devices (Figure 
S1A,B) that differed with regard to the type of lamp and the UVA1 
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spectrum (Figure S1C). Besides the conventionally used UVA1 device 
(340-400 nm) with an installed metal-halide lamp (exposure area of 
25 × 25 cm), the study used a UVA1 prototype (360-400 nm) with light-
emitting diode-based technology (exposure area of 30 × 30 cm with 
144 single LEDs) (both from Sellas Medizinische Geräte GmbH). Both 
UVA1 light sources were positioned and installed to emit the same ir-
radiation power of 50 mW/cm2. During the UVA1 treatments, the dis-
tance between the metal-halide lamp and the animal cage was 2 cm 
and between the LED-based UVA1 prototype and the cage 60 cm.
For UVA1 treatment, 50 000 cells were seeded onto 6-well cell 
culture plates and irradiated with different doses of UVA1 light (20 J/
cm2 - 640 minutes; 40 J/cm2 - 13 20 minutes; 60 J/cm2 - 20 00 min-
utes; 100 J/cm2 - 33 30 minutes). During UVA1 irradiation, cells 
were maintained in 2 ml of phosphate-buffered saline (PBS) (Sigma-
Aldrich). Untreated control cells and UVA1-treated cells simultane-
ously underwent a change in medium (2 mL DMEM) immediately 
after irradiation. Cells were incubated for 6 and 24 hours after UVA1 
treatment followed by RNA isolation.
Mice received a medium dose (60 J/cm2 - 20 00 minutes) and a 
high dose (100 J/cm2 - 3330 minutes) of UVA1 irradiation dependent 
on their assigned experimental group (Table S1).
Both the in vitro and the in vivo studies were conducted with 
the two UVA1 light sources (a metal-halide UVA1 lamp and the LED-
based UVA1 prototype) under the same conditions to allow a direct 
comparison. The only difference in the set-up was the use of a fan 
in the experiment with the metal-halide lamp to protect the animals 
from severe heat.
2.4 | RNA isolation and reverse transcription
Cellular RNA was isolated using the NucleoSpin® RNA Kit 
(Macherey-Nagel) according to the manufacturer's instructions. 2 µg 
of RNA was then transcribed into cDNA by reverse transcriptase 
reaction using the Super ScriptTM II Kit (Invitrogen, Thermo Fisher 
Scientific).
2.5 | Quantitative real-time PCR analysis
Cellular gene expression analysis consisted of quantitative real-
time PCR with specific sets of primers (Sigma-Aldrich) and condi-
tions (Table S2) using LightCycler technology (Roche Diagnostics) as 
described elsewhere.[24] PCR reactions were evaluated by melting 
curve analysis. ß-actin was amplified to ensure cDNA integrity and 
to normalize expression. Each real-time PCR was repeated at least 
3 times.
2.6 | Enzyme-linked immunosorbent assay (ELISA)
Cell supernatants were collected 48 hours after UVA1 treatment and 
of untreated control fibroblasts and were analysed by total MMP-1 
ELISA, respectively, according to the manufacturer's instruction. The 
human total MMP-1 ELISA (DuoSet ELISA Development System) was 
received from R&D Systems, Wiesbaden-Nordenstadt, Germany, 
and detects active and pro-Matrix Metalloproteinase-1. Each super-
natant was assayed in duplicates, and the entire experiments were 
performed three times with dermal fibroblasts from n = 6 different 
donors.
2.7 | MTT assay
The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide 
(MTT) test is based on the reduction in tetrazolium salt by mitochon-
drial enzymes to form coloured formazan as an indicator of vital-
ity.[25] To evaluate the cell vitality of human fibroblasts (n = 6) after 
UVA1 treatment, 10
4 cells/well were seeded onto a 96-well microti-
tre plate and irradiated with different doses of UVA1 light (20 J/cm
2 
- 640 minutes; 40 J/cm2 - 1320 minutes; 60 J/cm2 - 20 00 minutes; 
80 J/cm2 - 2640 minutes; 100 J/cm2 - 3330 minutes) or remained 
untreated. During UVA1 irradiation, cells were maintained in 100 µL 
of PBS. After irradiation, PBS was replaced by 100 µL of DMEM, and 
the microtitre plate was incubated under humid conditions in a 5% 
CO2incubatorat 37°C for 24 hours. 10 µL of MTT reagent (5 mg/mL 
in PBS, Sigma-Aldrich) was added directly to the medium in the wells 
of the microtitre plate and incubated for 4 hours. Insoluble formazan 
was formed in the cells in proportion to the activity of the dehy-
drogenases. The formazan was finally dissolved in 100 µL 20% SDS 
(sodium dodecyl sulphate, Sigma-Aldrich) and incubated overnight in 
the incubator. Absorbance of the dissolved solution was observed 
with a microtitre plate reader (MWG-Biotech) at 540 nm. Each sam-
ple was assayed in duplicates, and the entire experiments were con-
ducted three times.
2.8 | Histochemical analysis
Immunohistochemistry was conducted on formalin-fixed and paraf-
fin-embedded full-skin preparations from all mice (n = 6 mice per 
group). Skin sections measuring 2 µm were stained with anti-alpha-
smooth muscle actin (anti-α-SMA) antibody (EPR5368) (1:1000; 
Abcam) according to the following protocol: sections were depar-
affinized, rehydrated and placed into a steamer in Tris/EDTA buffer 
(pH 8) for 30 minutes. After cooling down to room temperature, the 
tissue slides were washed in PBS, incubated with the primary anti-
body at room temperature for 1 hour, washed again with PBS and 
incubated with Histofine solution (Nichirei Biosciences INC. Tokyo, 
Japan) for 30 minutes. Tissue slides were washed again with PBS 
and incubated with AEC substrate chromogen (ready to use; Dako-
Agilent) at room temperature in the dark for 15 minutes. The stain-
ing reaction was stopped with H2O, and counterstaining was done 
with haematoxylin (Roth).
H&E staining on murine skin sections was done as described 
previously.[26] Extracellular matrix accumulation in skin sections was 
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determined by staining with Sirius red/fast green.[27] The intensity 
of the Sirius red staining of the murine tissue sections was quanti-
fied with the image J software (http://www.imagej.softo nic.de) and 
expressed as a percentage of the total area. All tissue slides were 
scanned with a histo-scanner (PreciPoint, M8), and representative 
pictures were visualized.
2.9 | Analysis of collagen content
Collagen in mouse tissues was analysed with the QuickZyme colla-
gen assay according to the manufacturer's instructions (QuickZyme 
Biosciences).
2.10 | Statistical analysis
Data are expressed as mean values ± standard deviation (SD). Data 
were analysed with GraphPad Prism 5 software (GraphPad Software 
Inc). Groups were compared by one-way ANOVA with Tukey's hon-
estly significant difference (HSD) post hoc test analysis. Differences 
were considered statistically significant at P < .05.
2.11 | Study approval
The animal study was conducted according to the NIH Guide for the 
Care and Use of Laboratory Animals, with the appropriate permis-
sion from the Animal Rights Commission of the State of Bavaria, and 
approved by the Committee on the Ethics of Animal Experiments 
of the University of Regensburg, Germany (permit number 55.2 
DMS-2532-2-461).
3  | RESULTS
The study purpose was to evaluate molecular and histological ef-
fects of an LED-based UVA1 prototype (spectral range 360-400 nm) 
on human fibroblasts and dermal fibrosis in a bleomycin-induced 
mouse model of scleroderma in comparison to conventional UVA 
treatment with a high-pressure metal-halide lamp (spectral range 
340-400 nm). For the in vitro approach, different UVA1 dose regi-
mens (20, 40, 60, 80 and 100 J/cm2) were evaluated, and for the in 
vivo approach 2 different treatment regimens (high dose: 100 J/cm2 
and medium dose: 60 J/cm2).
3.1 | UVA1 phototherapy equipment and 
emission spectrum
Figure S1 shows the exposure unit and the emission spectrum of the 
UVA1 metal-halide high-pressure lamp (SELLASOL) (Figure S1A, C) 
and the LED-based UVA1 prototype (Figure S1B,C).
3.2 | Examination of morphology and cell vitality of 
human fibroblasts after UVA1 treatment
To compare the two UVA1 light sources with respect to cell viabil-
ity, cell morphology and cell vitality were determined 24 hours after 
UVA1 treatment by means of an MTT test. Human fibroblasts ex-
posed to high UVA1 doses (80 and 100 J/cm
2) appeared swollen, 
broken and round, and the damage was most critical after treatment 
with either light source (Figure 1A). Single UVA1 treatments with 
up to 60 J/cm2 did not change the morphology of the fibroblasts. 
Cell vitality significantly decreased with increasing UVA1 doses 
(Figure 1B). Doses > 60 J/cm2 were defined as the irradiation limit 
for both UVA1 light sources and were not used in further cell culture 
experiments.
3.3 | Effects of UVA1on cytokines, growth 
factors and collagen metabolism in fibroblasts
mRNA expression of IL-1α and IL-6, which was initially analysed 6 hours 
after exposure to UVA1, was induced after treatment with both the 
metal-halide lamp and the LED-based prototype in comparison with 
untreated control. mRNA expression did not seem to be dependent 
on the UVA1 dose (Figure 2A,B). Interestingly, induction of IL-1α was 
significantly higher with the LED-based UVA1 prototype at the low 
dose of UVA1 of 20 J/cm
2. Next, the mRNA expression levels of matrix 
metalloproteinase-1 (MMP-1), collagen type 1 (Col-1), and transform-
ing growth factor ß-1 and transforming growth factor ß-2 (TGFß-1 and 
TGFß-2) were examined 24 hours after UVA1 exposure. MMP-1 mRNA 
expression had increased after UVA1 treatment with the highest induc-
tion at the UVA1 dose of 60 J/cm
2 for either light source. Here, the LED-
based prototype showed a significant induction advantage (Figure 2C). 
Investigations of MMP-1 at the mRNA level were supplemented with 
data showing the human total MMP-1 (human active MMP-1 and pro-
MMP-1) in cell culture supernatants collected 48 hours after UVA1 
treatment. The results showed that in the supernatants collected from 
UVA1-treated fibroblasts significantly more total MMP-1 protein can 
be detected when using a UVA1 dose of 40 or 60 kJ/cm
2 compared to 
the untreated control (Figure S2). In analogy to the mRNA data, a dose 
of 60 kJ/cm2 also showed a significantly increased amount of total 
MMP-1 protein in the supernatant when using the LED UVA1 device 
compared to the metal-halide lamp. The expression of Col-1 was sig-
nificantly down-regulated at doses ≥40 J/cm2. Lower UVA1 doses with 
either light source did not seem to have any reducing effect on the 
mRNA expression level of Col-1 (Figure 2D). Expression of TGFß-1 was 
induced after UVA1 irradiation of normal human fibroblasts compared 
to untreated cells (Figure 2E). Interestingly, mRNA induction seemed 
to be dose-dependent for metal-halide UVA1 treatment and not dose-
dependent for LED-based UVA1 treatment. In contrast, TGFß-2 was 
down-regulated with the strongest effect at the dose of 60 J/cm2 for 
either light source (Figure 2F). In summary, these results indicate that 
both UVA1 light sources affect identical biological mechanisms in fibro-
blasts with similar or even better effects of the new LED-based light 
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source with a UVA1 spectrum (340-400 nm) that is 20 nm narrower 
than that of the conventional metal-halide lamp (460-400 nm).
3.4 | Evaluation of dermal thickness, collagen 
content and the number of α-SMA–positive 
myofibroblasts after UVA1 treatment
The biological effects of the two UVA1 light sources were com-
pared by means of a well-established bleomycin-induced murine 
scleroderma model in a preclinical in vivo approach.[23] After 
30 subcutaneous bleomycin injections, the mice had developed 
dermal sclerosis and were divided into different phototherapeu-
tic treatment groups (Table S1). UVA1-treated groups (groups 3-6) 
received 30 UVA1 irradiation sessions and 10 additional bleomy-
cin injections to maintain the status of sclerosis. The mean der-
mal thickness of the bleomycin control group 2, which contains 
30 bleomycin injections and 10 additional bleomycin injections to 
maintain the status of sclerosis was 550.81 µm (Std. D. ± 102.8) 
in comparison with 186.51 µm (SD ± 34.8) in the group of healthy 
mice (group 1). Dermal thickness was significantly reduced after 
high-dose (100 J/cm2) UVA1 treatment with the metal-halide lamp 
F I G U R E  1   Morphology and vitality of fibroblasts after UVA1 treatment. A, Fibroblasts (#9F0438 as example) were exposed to different 
UVA1 doses (20, 40, 60, 80, and 100 J/cm
2) or remain untreated (ctrl.; 0 J/cm2). Cells treated with high UVA1 doses (80 and 100 J/cm
2) 
appeared swollen, broken and round. Scale bar: 500 µm. B, Cell vitality (MTT test) significantly decreased with increasing UVA1 doses 
(fibroblasts from n = 6 different donors) (*P < .05, ANOVA with Tukey's multiple comparison test). No significant differences were found 
between the two light sources
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(group3: 426.10 µm; SD ± 58.6) and the LED-based UVA1 proto-
type (group 4:413.10 µm; SD ± 31.2) in comparison with group 2 
(Figure 3A). Dermal thickness was also reduced after medium-dose 
UVA1 treatment regimens, but the reduction was not significant 
with either light source in comparison with the untreated group 2 
(group 5:446.20 µm; SD ± 80.70; group 6:441.30 µm; SD ± 56.4). 
The collagen content in the affected skin after UVA1 treatment 
was histologically analysed by means of Sirius red/fast green stain-
ing (Figure 4B) and image analysis (Figure 3B) and quantified using 
a hydroxyproline assay (Figure 3C). The amount of collagen was 
reduced after each UVA1 treatment regimen; however, compared 
to the bleomycin-only group (group 2), the reduction was only 
significant after high-dose treatment with either light source 
(Figure 3C). Finally, the number of α-SMA–positive myofibroblasts 
was determined by a dermato-histopathologist. Myofibroblasts 
were significantly reduced after high-dose UVA1 treatment with 
the metal-halide lamp and medium-dose UVA1 treatment with the 
LED-based UVA1 prototype (Figure 3D). The obviously stronger 
α-SMA staining in groups 3-6 (Figure 4C) was due to the blood ves-
sels that were also α-SMA positively stained and whose synthesis 
is known to increase after UVA1 irradiation.
[28] In summary, these 
in vivo results indicate that both UVA1 light sources are effective 
F I G U R E  2   Gene expression marker 
analyses in human fibroblasts after UVA1 
treatment. Different fibroblasts (n = 6 
different donors) were exposed to UVA1 
(metal-halide UVA1 or LED-based UVA1) 
using different treatment regimens (20, 
40 and 60 J/cm2) or remain untreated 
(ctrl.; 0 J/cm2). RNA was isolated 6 or 24 h 
after treatment as indicated in the text, 
and different sclerosis-related molecular 
markers were analysed. A, IL-1α, (B) IL-6, 
(C) MMP-1, (D) Col-1, (E) TGFß-1 and (F) 
TGFß-2 (*#P < .05, ANOVA with Tukey's 
multiple comparison test)
     |  1205ARNDT eT Al.
in reducing sclerosis in localized scleroderma with minor differ-
ences according to the dose of UVA1 irradiation applied.
4  | DISCUSSION
The aim of this study was to evaluate the impact of a new LED-
based UVA1 prototype with a spectral range of 360 to 400 nm on 
the treatment of LS. Normal human fibroblasts and a dermal fibro-
sis mouse model were used for analysis. In terms of biosafety and 
patient comfort, LED-based UVA1 light technology offers clear 
advantages over conventional metal-halide lamps with a broader 
spectral range of 340 to 400 nm. Next to the narrower and less 
harmful UVA1 spectrum, the LED-based UVA1 prototype has the 
advantage of less heat development and shorter treatment times 
at the same irradiation intensity.[29] However, the molecular and 
histological effects are also decisive when comparing different 
UVA1 light sources. Therefore, we analysed the effects on cell 
morphology, cell vitality, gene expression of sclerosis-relevant 
marker molecules, dermal thickness, collagen content and the sta-
tus of myofibroblast activation in vivo.
First of all, we focused on the morphology and vitality of nor-
mal human fibroblasts. Different UVA1 doses (20, 40, 60, 80 and 
100 J/cm2) were examined, and morphological changes (swollen, 
broken and round) were observed at doses of 80 J/cm2 and higher. 
No morphological differences were found between the conventional 
lamp and the LED-based prototype. Cell vitality decreased dose-de-
pendently and was significantly reduced after doses of 80 J/cm2 and 
higher with either light source. Hereby, the narrower UVA1 spectrum 
of the LED-based UVA1 prototype did not seem to affect cell vital-
ity. Up to date, only a few murine studies are available using a nar-
rowband UVA1 light source for the treatment of scleroderma.
[30,31] 
Karpec and coauthors described the safety and efficacy of 365 nm 
LED-based UVA1 phototherapy in bleomycin-induced scleroderma in 
F I G U R E  3   Evaluation of dermal thickness, collagen content and the number of α-SMA–positive myofibroblasts in a bleomycin-induced 
scleroderma model after UVA1 treatment. A, Dermal thickness was determined in µm in the 6 mice groups. Representative images of mice 
(n = 6 mice per group) were taken, and 5 measurements per image were used for the calculation (*#P < .05, ANOVA with Tukey's multiple 
comparison test). B, Determination of the fibrotic region by quantifying the Sirius red-positive area by image analysis (*P < .05, ANOVA with 
Tukey's multiple comparison test). C, Protein quantification of total collagen in the dermis within the 6 mice groups (n = 6 mice per group) 
(*P < .05, ANOVA with Tukey's multiple comparison test). D, Quantification of α-SMA–positive fibroblasts (myofibroblasts) (average of three 
hpf/animal; n = 6 animals per group) (*#P < .05, ANOVA with Tukey's multiple comparison test). SMA, smooth muscle actin; hpf, high-power 
field
F I G U R E  4   Histological overview of the 
bleomycin-induced scleroderma model 
after UVA1 treatment. Representative 
images of (A) H&E, (B) Sirius red/fast 
green and (C) α-SMA–stained sections of 
local skin fibrosis in different treatment 
groups (group 1: healthy control; group 2: 
bleomycin (Bleo) control; group 3: metal-
halide UVA1 (100 J/cm
2); group 4: LED 
UVA1 (100 J/cm
2); group 5: metal-halide 
UVA1 (60 J/cm
2); and group 6: LED-based 
UVA1 (60 J/cm
2). α-SMA–stained vessel 
structures are strongly increased after 
UVA1 treatment and are marked with 
dotted arrows in the enlarged sections. 
Full arrows in the enlarged sections 
indicate α-SMA positively stained 
fibroblasts. Scale bars: 500 µm
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mice,[31] but the optimum UVA1 spectrum for scleroderma treatment 
has not yet been determined and needs to be examined further.
To determine possible differences between metal-halide lamps 
and the LED-based UVA1 prototype on the molecular level, we ana-
lysed the gene expression of UVA1-affected biomolecules involved 
in scleroderma. Increased MMP-1 expression is one of the most im-
portant indicators for successful UVA1 treatment and significantly 
improves the clinical condition of LS.[11] MMP-1 is specifically re-
sponsible for the breakdown of collagen. Collagen type I (Col-1) is 
the predominant collagen component of the skin and plays a central 
role in LS development. Its excessive production by fibroblasts leads 
to the typical phenotype of dermal fibrosis with accompanying skin 
hardening due to pathological collagen excess in the dermis. The two 
biomarkers MMP-1 and Col-1 interact with each other and maintain 
the balance of collagen metabolism in healthy fibroblasts. UVA1-
induced MMP-1 induction in fibroblasts and the reduction in Col-I 
has been described in many studies.[32-36] In the present study, we 
also observed significant MMP-1 induction at the dose of 60 J/cm2 
with either light source and a higher activation rate in fibroblasts 
irradiated with narrowband LED-based UVA1. This higher induction 
capacity of LED-based UVA1 for MMP-1 maybe a clear advantage of 
the LED-based UVA1 light source that potentially results in a better 
clinical response to treatment. So far, we do not know the mechanism 
responsible for the higher induction capacity for MMP-1 when using 
the LED-based UVA1 lamp. However, comparison of both spectra 
shows that the LED emission spectrum shows three distinct maxima 
at about 367, 375 and 385 nm. When neglecting the small peaks, the 
metal-halide lamp shows five maxima, whereas three maxima can be 
found in the spectral range of the LED emission spectrum at about 
366, 377 and 384 nm. Thus, the maxima in the comparable wave-
length show almost the same wavelengths. Besides the small part 
in the visible spectrum, the major difference of both spectra can be 
assigned to the short wavelength part of the UVA spectrum. Thus, 
at equal radiant exposure, the LED-based UVA1 lamp provides more 
photons in the short wavelength range from about 360 to 400 nm. 
A set of molecules in cells like flavins and vitamin A show absorption 
maximum in the range of 370-380 nm.[37,38] Part of these molecules 
efficiently generate singlet oxygen which in turn may induce MMP-
1.[39,40] This hypothesis is purely speculative and must be investi-
gated in further studies.
In addition to MMP-1 induction, our study also showed reduc-
tion in Col-1. Although collagen balance is of particular importance 
in sclerotic diseases, collagen degradation by UVA1 treatment plays 
a relatively minor but not less important role than the induction of 
MMP-1. In percentage terms, UVA1 irradiation has a significantly 
stronger effect on MMP-1 activation than on the reduction in Col-
1[32] as confirmed by our study.
In addition to the intervention in the collagen balance of fi-
broblasts, another important mechanism of UVA1 irradiation is 
its immunomodulatory effect. This effect particularly concerns 
pro-inflammatory cytokines such as IL-1α and IL-6 that signal me-
diate functions inside and outside a cell. Stimuli of cytokine pro-
duction in the cells are different stress factors such as exposure 
to UV light. The synthesis of pro-inflammatory cytokines forms a 
mutually stimulating network, in which IL-1α plays a special role. 
IL-1α may influence the collagen metabolism and is a major stimu-
lus for the synthesis of other profibrotic regulatory proteins such 
as IL-6 or IL-8.[41,42] Kreuter and colleagues described significantly 
down-regulated mRNA expression of IL-6 and IL-8 after UVA1 treat-
ment in patients with LS.[43] Vielhaber et al controversially discussed 
in their study that increased UVA1-induced MMP-1 production is 
connected with the upregulation of the cytokine IL-1α and the re-
sulting increase in IL-6 synthesis.[44] Increased IL-1α and IL-6 gene 
expression after UVA1 irradiation of fibroblasts was also found by 
Wlaschek et al[36,40] Any comparison of study results should distin-
guish between normal fibroblasts and LS-derived fibroblasts. Our 
study involved normal fibroblasts. Similar to the results of Wlaschek 
et al,[36,40] we observed a significant induction of IL-1α and IL-6 ex-
pression for both UVA1 light sources. In addition, the growth factors 
of the TGFß family are considered to be further important indicators 
for fibrosis and play an essential role in scleroderma. In the dermis, 
TGFß stimulates the proliferation of dermal fibroblasts, which in turn 
secrete increased amounts of ECM components such as Col-1 and 
have a reducing effect on MMP-1 expression.[45-48] In addition, TGFß 
may suppress the production of IL-1, TNFα and IL-8, which in turn 
shows the interplay between pro- and anti-inflammatory functions 
in cytokine-mediated inflammatory reactions.[49] The two most im-
portant isoforms of TGFß are TGFß-1 and TGFß-2, both crucial fac-
tors in the pathogenesis of fibrosis.[47,50-53] In activated scleroderma 
fibroblasts, the growth factor TGFß-1 is excessively secreted.[45] 
In addition, mRNA gene expression of TGFß in lesional skin areas 
significantly decreases after UVA1 therapy in patients with LS.
[45] 
Other in vivo studies using normal human skin samples yielded con-
tradictory results. Quan et al described the significant upregulation 
of TGFß-1 combined with a simultaneous decrease in TGFß-2 after 
exposure to UV irradiation.[54] In experiments with skin fibroblasts, 
Yin et al also observed the significant induction of TGFß-1 after UVA 
treatment.[48] The results of Quan et al and Yin et al[48,54] are also re-
flected in our study. 24 hours after UVA1 exposure, TGFß-1 expres-
sion was increased simultaneously with reduced TGFß-2 expression 
in normal fibroblasts.
Effective UVA1 treatment of scleroderma in vivo decreases der-
mal thickness primarily due to the degradation and reduction in col-
lagen.[32] In our in vivo experiment, all groups except control group 
1 received bleomycin injections and developed the typical picture 
of the fibrosis mouse model described by Yamamoto et al[20-23] The 
bleomycin control group 2 clearly showed thicker dermis than groups 
3, 4, 5 and 6 that were additionally treated with UVA1. Also clearly 
visible were the fat cells displaced by dermal fibrosis that resulted in 
complete absence of these cells due to highly pronounced fibrosis, es-
pecially in control group 2 of this study. Here, fat cells are replaced by 
fibrotic tissue through adipocyte-myofibroblast transformation.[55,56] 
Slight regeneration of fatty tissue was observed in the experimen-
tal groups treated with UVA1. Increased myofibroblast activity and 
associated profibrotic processes significantly contributing to the de-
velopment of fibrosis[21,57] could be observed in the α-SMA stains of 
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groups 2-6 treated with bleomycin. Quantification of α-SMA–pos-
itive fibroblasts by a dermato-histopathologist showed a decrease 
in activated myofibroblasts after UVA1 treatment. Myofibroblasts 
were significantly reduced compared to the untreated control 
group 2 after high-dose treatment with the metal-halide lamp 
(group 3). Interestingly, similar significant effects could be already 
achieved with a medium dose of the LED-based UVA1 prototype 
(group 6). The induction of neoangiogenesis occurring as wound 
healing process in UVA1-treated mice could also be observed by 
means of α-SMA staining, as Trompezinski et al showed in an ex-
perimental approach.[28] These α-SMA–stained vascular structures 
dominate the histological picture of the UVA1 treated groups and 
were of course excluded in the quantification of α-SMA–positive 
myofibroblasts.
Compared to already published results, our histological anal-
ysis showed that 30 irradiations (cumulative dose of 3000 J/
cm2) with a high UVA1 dose (100 J/cm
2) with either light source 
significantly reduced the dermal diameter by about 25%; the re-
duction achieved with medium-dose UVA1 treatment (60 J/cm
2) 
(cumulative dose of 1800 J/cm2) was about 20%. These results 
indicate that both light sources are effective in treating sclerosis 
and have almost the same effect on reducing dermal thickness. 
Karpec and colleagues described in their animal study that even 
a cumulative dose of UVA1 with a narrowband (365 ± 5 nm) LED-
based UVA1 light source that was 5 times lower than that of con-
ventional broadband UVA1 lamps had almost the same effect on 
decreasing dermal thickness (skin thickness was reduced by 34% 
after irradiation with a cumulative dose of 600 J/cm2 and by 36% 
using 3000 J/cm2).[31] In our similar mouse model, reduction in the 
dermal diameter in the 129Sv/Ev mouse strain was lower than that 
achieved by Karpec using two different devices for UVA1 irradi-
ation. This difference may be due to the different animal strains 
(129Sv/Ev versus DBA/2), differences in the performance of the 
bleomycin-induced sclerosis model (maintenance of the sclerosis 
status versus no further bleomycin treatment during the period of 
UVA1 therapy) or the different spectral ranges of the LED source 
(360-400 nm vs 365 ± 5 nm).
Nevertheless, this study indicates that the two tested UVA1 light 
sources are effective in reducing skin sclerosis with similar or even 
better effects of the new LED light source on the histological and 
molecular level. In terms of biosafety and patient comfort, the LED-
based UVA1 light source offers clear advantages such as an arrower 
UVA1 spectrum, less heat generation and shorter treatment times. 
Further clinical studies are required to confirm these results in pa-
tients with LS or related sclerotic skin diseases such as eosinophilic 
fasciitis, lichen sclerosus et atrophicus or chronic sclerodermiform 
graft-versus-host (GvHD) disease, in which UVA1 phototherapy is 
also a treatment option.
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Figure S1. UVA1-phototherapy equipment.
Figure S2. Total MMP-1 protein in the supernatants of UVA1-treated 
fibroblasts.
Table S1. Timeline overview of the mouse study. Bleomycin (Bleo)-
injections for 30 d (5 times per week for 6 wk; except for healthy 
control group 1 treated with PBS). 30 UVA1-irradiation sessions 
(5 times per week for 6 wk; except for healthy control group 1 and 
Bleo control group 2) were followed by 10 additional Bleo injections 
(1-2 times per week for 6 wk; except for healthy control group 1 
treated with PBS) to maintain the sclerosis status.
Table S2. Primers and conditions. Quantitative real-time PCR was 
conducted with specific sets of primers and conditions as indicated 
in this table. Ann, annealing temperature; melt, melting temperature.
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